Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

16 Risultati di ricerca.

Non-Surgical Intervention GSK study Prostatic neoplasms NCT00883909

- 26/11/17 - 1 modulo, 3 itemgroups, 12 elementi, 1 linguaggio

Itemgroups: Administrative data, Intervention non-surgical Prostate Cancer, Intervention non-surgical

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

Concomitant Medications GSK study Prostatic neoplasms NCT00883909

- 26/11/17 - 1 modulo, 3 itemgroups, 15 elementi, 1 linguaggio

Itemgroups: Administrative data, Concomitant Medications, Concomitant Medication

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

Hypofractionated Radiotherapy in Prostate Cancer NCT01368055 - Eligibility Criteria

- 15/03/21 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01368055

HistoScanning-based Brachytherapy in Prostate Cancer NCT01409876 - Eligibility Criteria

- 22/05/19 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Phase II trial looking at the feasibility of HistoScanning-based dose-painting image-guided interstitial brachytherapy in non-metastatic prostate cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01409876

SABR in High Risk Prostate Cancer (SATURN) NCT01953055 - Eligibility Criteria

- 22/05/19 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN); ODM derived from: https://clinicaltrials.gov/show/NCT01953055

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 11 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 11

- 24/05/17 - 1 modulo, 22 itemgroups, 135 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 10 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 10

- 24/05/17 - 1 modulo, 22 itemgroups, 135 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 9 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 9

- 24/05/17 - 1 modulo, 22 itemgroups, 135 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 8 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 8

- 24/05/17 - 1 modulo, 22 itemgroups, 135 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 7 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 7

- 24/05/17 - 1 modulo, 22 itemgroups, 135 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 6 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 6

- 24/05/17 - 1 modulo, 22 itemgroups, 139 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Cycle 4 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Cycle 4

- 24/05/17 - 1 modulo, 23 itemgroups, 136 elementi, 1 linguaggio

Itemgroups: Visit Information, Vital Signs, Laboratory Tests Hematology, Laboratory Tests Biochemistry, Premedication, Investigational Product Administration - Prednisone, Investigational Product Administration - Cabazitaxel, Interruption - Cabazitaxel, Circulating free plasma DNA - Blood Sampling, Macroscopic Hematuria, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.